CLDX : Analysis & Opinions
November 15, 2016Positive pre-clinical data for its CDX-1140 cancer drug has buoyed the beleaguered company.
November 8, 2016Celldex reported a 3Q loss of 29 cents a share, above Wall Street estimates.
November 2, 2016Celldex is buying cancer drug maker Kolltan for $62.5 million in stock.The deal includes $172.5 million in future payments.
September 20, 2016While the company has a large pipeline of drugs under development, its short-term sustainability is questionable amid a significant ...